Pharmacokinetics Study of FIA586 in Participants With Mild and Moderate Hepatic Impairment
Status:
Not yet recruiting
Trial end date:
2022-04-14
Target enrollment:
Participant gender:
Summary
This is a Phase I study designed to characterize the pharmacokinetics (PK), safety, and
tolerability of a single oral dose of FIA586 in participants with mild and moderate hepatic
impairment (HI) compared to matched healthy participants.The information obtained in this
study will help to determine whether dosage adjustment for FIA586 is necessary in patients
with advanced liver fibrosis who have mild to moderate HI.